EL7.AI
StocksMediumUpdated•Originally published 9 March 2026•Updated 9 March 2026•
1 min read

Dianthus Therapeutics Accelerates Phase 3 CIDP Trial Following Positive Clinical Data

Key Facts

1Early GO decision reached for Phase 3 CAPTIVATE CIDP trial ahead of Q2 2026 guidance.
2Response criteria met with 20 confirmed responders achieved with fewer than 40 planned participants.
3The company reported its financial results for the fourth quarter and full fiscal year 2025.

Dianthus Therapeutics (DNTH) has announced an early 'GO' decision for its Phase 3 CAPTIVATE trial targeting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), significantly ahead of its Q2 2026 guidance. CIDP is a rare autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, leading to progressive muscle weakness and sensory loss lasting over 8 weeks. The decision was triggered after the clinical program met its response criteria, achieving 20 confirmed responders among fewer than 40 participants. Alongside these milestones, the company released its financial results for the fourth quarter and full fiscal year 2025. This acceleration highlights the potential efficacy of the treatment and may shorten the path to market. Investors view these developments as a significant positive catalyst for the company's long-term growth and clinical pipeline validation.